Orion Oyj holds the cleaner structural position, with growth as the main driver and valuation adding further support. Novo Nordisk A/S still has the edge on valuation, which keeps the comparison from looking entirely one-sided. The market setup broadly confirms the structural lead — Orion Oyj holds the more constructive position. That puts structure and market broadly in agreement — Orion Oyj's lead looks more confirmed than conflicted.
The comparison is based on similar long-term financial trajectories, not sector labels. Both peer scores are relative to the STOXX 600 universe, making them directly comparable.
Growth still does most of the heavy lifting in this comparison. Orion Oyj leads by 17 points on the overall comparison score.
Both operate in: Drug Manufacturers - General
This comparison is based on industry proximity, not on functional trajectory similarity. NOVO-B.CO and ORNBV.HE share the same industry classification.
For a similarity-based comparison, see how Novo Nordisk A/S and Orion Oyj each position within their functional peer groups in AssetNext.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
The largest gaps do not all point in the same direction.
Left means cheaper relative valuation. Higher means stronger structure.
Orion Oyj occupies the cheaper side of the setup map, although Novo Nordisk A/S still holds the stronger structural profile.
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
Where NOVO-B.CO and ORNBV.HE each sit in their own 5-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
Revenue growth reinforces the category-level growth lead.
Absolute pricing still looks more supportive for Novo Nordisk A/S, with a forward P/E that is 3 turns lower there.
The growth edge is decisive, even though current pricing and valuation still lean somewhat toward Novo Nordisk A/S.
Break down the NOVO-B.CO vs ORNBV.HE comparison across all dimensions with the full interactive tool.
Explore how NOVO-B.CO and ORNBV.HE each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.